Literature DB >> 1525456

Leuprolide acetate elevates prolactin during ovarian stimulation with gonadotropins.

D R Meldrum1, M I Cedars, F Hamilton, D Huynh, A Wisot, B Marr.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether gonadotropin-releasing hormone agonist further increases the prolactin rise accompanying ovarian stimulation.
DESIGN: Serum prolactin concentrations were compared between cycles with and cycles without the use of leuprolide acetate (LA) matched for estradiol levels. Relationships of prolactin levels to cycle outcomes were examined.
SETTING: The study took place at a private fertility center. PATIENTS: Patients were women receiving stimulation for oocyte retrieval using human menopausal gonadotropins.
INTERVENTIONS: No interventions were used. MAIN OUTCOME MEASURES: Serum prolactin level, fertilization rate, embryo quality, and pregnancy were the main outcome measures.
RESULTS: Higher serum prolactin was associated with both higher estradiol levels and use of LA but did not have any effects on fertilization rate, embryo quality, or occurrence of pregnancy.
CONCLUSION: LA stimulates prolactin release during ovarian stimulation but without apparent consequence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525456     DOI: 10.1007/bf01203823

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  10 in total

1.  Inhibition of prolactin secretion by antiserum to the alpha- and beta-subunits of gonadotropin.

Authors:  R E Blackwell; P N Garrison
Journal:  Am J Obstet Gynecol       Date:  1987-04       Impact factor: 8.661

2.  Transient hyperprolactinemia during cycle stimulation and its influence on oocyte retrieval and fertilization rates.

Authors:  W P Hummel; M R Clark; L M Talbert
Journal:  Fertil Steril       Date:  1990-04       Impact factor: 7.329

3.  GnRH agonists as adjuncts for in vitro fertilization.

Authors:  D Meldrum
Journal:  Obstet Gynecol Surv       Date:  1989-05       Impact factor: 2.347

4.  Transient hyperprolactinemia during cycle stimulation: influence on the endocrine response and fertilization rate of human oocytes and effects of bromocriptine treatment.

Authors:  A Reinthaller; C Bieglmayer; J Deutinger; P Csaicsich
Journal:  Fertil Steril       Date:  1988-03       Impact factor: 7.329

5.  Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women.

Authors:  D R Meldrum; Z Tsao; S E Monroe; G D Braunstein; J Sladek; J K Lu; W Vale; J Rivier; H L Judd; R J Chang
Journal:  J Clin Endocrinol Metab       Date:  1984-04       Impact factor: 5.958

6.  Induction of prolactin release by LRF and LRF-agonist.

Authors:  S S Yem; J D Hoff; B L Lasley; R F Casper; K Sheehan
Journal:  Life Sci       Date:  1980-06-09       Impact factor: 5.037

7.  Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.

Authors:  E M Smith; F W Anthony; S C Gadd; G M Masson
Journal:  BMJ       Date:  1989-06-03

8.  The incidence of transient hyperprolactinemia in gonadotropin-stimulated cycles for in vitro fertilization and its effect on pregnancy outcome.

Authors:  G E Hofmann; A L Denis; R T Scott; S J Muasher
Journal:  Fertil Steril       Date:  1989-10       Impact factor: 7.329

9.  Bromocriptine inhibition of anesthesia-induced hyperprolactinemia: effect on serum and follicular fluid hormones, oocyte fertilization, and embryo cleavage rates during in vitro fertilization.

Authors:  V M Sopelak; N S Whitworth; P F Norman; B D Cowan
Journal:  Fertil Steril       Date:  1989-10       Impact factor: 7.329

10.  The influence of transient hyperprolactinemia on hormonal parameters, oocyte recovery, and fertilization rates in in vitro fertilization.

Authors:  Y Gonen; R F Casper
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-06
  10 in total
  2 in total

Review 1.  Local and systemic factors and implantation: what is the evidence?

Authors:  Chelsea Fox; Scott Morin; Jae-Wook Jeong; Richard T Scott; Bruce A Lessey
Journal:  Fertil Steril       Date:  2016-03-03       Impact factor: 7.329

Review 2.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.